1. Acknowledgment to Referees

   Acknowledgement to Referees 18 November 2015 Pages: 449 - 451

2. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents

   • Pilar García-Alfonso
   • Ana Ferrer
   • Ricardo Lara

   Review Open access 11 March 2015 Pages: 453 - 465

3. Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment

   • Gregory Benedetto
   • C. Greer Vestal
   • Christine Richardson

   Review 21 May 2015 Pages: 467 - 485

4. Renal Toxicities of Targeted Therapies

   • Anum Abbas
   • Mohsin M. Mirza
   • Ketki Tendulkar

   Review Article 30 April 2015 Pages: 487 - 499

   

5. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo

   • Natalie R. Young
   • Christian Soneru
   • Ezra E. W. Cohen

   Original Research Open access 06 January 2015 Pages: 501 - 508

   

6. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study

   • Michael P. Kosty
   • Antoinette J. Wozniak
   • Thomas J. Lynch Jr.

   Original Research 06 January 2015 Pages: 509 - 516

   

7. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

   • Matteo Santoni
   • Sebastiano Buti
   • Stefano Cascinu

   Original Research 06 January 2015 Pages: 517 - 522

   

8. A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma

   • Livius Penter
   • Bert Maier
   • Matthias Truss

   Original Research 06 January 2015 Pages: 523 - 533

   

9. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer

   • Yue Zhao
   • Lu Zhao
   • Peter Camaj

   Original Research 03 February 2015 Pages: 535 - 548

   

10. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study

    • Ondrej Fiala
    • Jindrich Finek
    • Ondrej Topolcan

    Original Research 15 April 2015 Pages: 549 - 555

    

11. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

    • Katerina Kubackova
    • Bohuslav Melichar
    • on behalf of the Czech Renal Cancer Cooperative Group

    Original Research 23 April 2015 Pages: 557 - 563

    

12. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines

    • Yi Shi
    • Lin Sun
    • Wanguo Wei

    Original Research 29 April 2015 Pages: 565 - 573

    

13. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX

    • Yufeng Wang
    • Yasuhiro Kuramitsu
    • Kazuyuki Nakamura

    Original Research Article 05 May 2015 Pages: 575 - 581

    

14. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

    • Evelyn Despierre
    • Ignace Vergote
    • on behalf of the European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), Australia New Zealand Gynaecological Oncology Group (ANZGOG), and the Mario Negri Gynecologic Oncology group (MaNGO)

    Original article 26 May 2015 Pages: 583 - 596

    

15. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor

    • Guhyun Kang
    • Byung Noe Bae
    • Kyoung-Mee Kim

    Day-to-Day Practice 05 March 2015 Pages: 597 - 601